Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

[1]  R. Labianca,et al.  Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Gibbs,et al.  Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. , 2020, Journal of Clinical Oncology.

[3]  M. Gerken,et al.  Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients , 2020, Langenbeck's Archives of Surgery.

[4]  J. Desai,et al.  BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Kloor,et al.  The Association Between Mutations in BRAF and Colorectal Cancer–Specific Survival Depends on Microsatellite Status and Tumor Stage , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  J. Meyerhardt,et al.  NCCN Guidelines Insights: Colon Cancer, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[8]  Jeffrey S. Morris,et al.  Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes , 2017, Clinical Cancer Research.

[9]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  David M. Jones,et al.  PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry , 2017, Journal of Clinical Pathology.

[11]  J. Meyerhardt,et al.  Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502). , 2017 .

[12]  D. Sargent,et al.  Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer , 2017, Journal of the National Cancer Institute.

[13]  N. Kemeny,et al.  Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations , 2017, Clinical Cancer Research.

[14]  D. Sargent,et al.  Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials , 2017, JAMA oncology.

[15]  M. Meyerson,et al.  Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location , 2016, Clinical and translational gastroenterology.

[16]  P. Laurent-Puig,et al.  Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. , 2016, JAMA oncology.

[17]  C. Tournigand,et al.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Mingyang Song,et al.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis , 2015, Gut.

[19]  C. Huttenhower,et al.  Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. , 2015, JAMA oncology.

[20]  M. Ladanyi,et al.  BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.

[21]  L. Collette,et al.  Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[22]  D. Sargent,et al.  KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) , 2014, Clinical Cancer Research.

[23]  R. Labianca,et al.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  H. Brenner,et al.  Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany , 2013, PloS one.

[25]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[26]  Levi Waldron,et al.  Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum , 2012, Gut.

[27]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[28]  H. Lenz,et al.  Gender Disparities in Metastatic Colorectal Cancer Survival , 2009, Clinical Cancer Research.

[29]  Peter W. Laird,et al.  Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening , 2008, Cancer Epidemiology Biomarkers & Prevention.

[30]  L. Aaltonen,et al.  BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.

[31]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[32]  V. Heinemann,et al.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.